Maheshwari Anshul sold $87K of SIBN

Maheshwari Anshul (Chief Financial Officer) sold 4,665 shares of SI-BONE, Inc. (SIBN) at an average of $18.65 ($18.62–$18.68) across 2 trades on 2026-08-17.

Original reporting
SEC EDGAR · Maheshwari Anshul
Published Aug 18, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
high confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may influence short-term sentiment, but it does not provide new company performance or guidance data.

02

Market read

Traders may monitor insider activity for sentiment, but this specific transaction is small and lacks fundamental catalysts.

03

What to watch

Insider sales are often planned for diversification or tax; the filing does not indicate any change in business outlook or risk.

Relevance 3/10Novelty 2/10Timing: filed after-hours on Aug. 18, covering sales on Aug. 17

Background

This is an SEC Form 4 insider transaction for SI-BONE, Inc., reported by the CFO.

Company-level read

Ticker impact

$SIBNNeutralHigh confidence
Context

SI-BONE CFO Maheshwari Anshul sold 4,665 shares in open-market transactions totaling about $87.0K, per Form 4 filed Aug. 18.

Expected impact

Low near-term impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale, small relative to typical company market caps, and provides no new operational or guidance information.

Market effects

Minimal, as the disclosure is company-specific insider activity without sector-wide signal.

None indicated.

None indicated.

Counterpoint

The absence of a disclosed 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as caution.

Key entities

  • SI-BONE, Inc.

    Company whose CFO reported an open-market sale of shares via SEC Form 4.

  • Maheshwari Anshul

    Chief Financial Officer who sold 4,665 shares across two trades on Aug. 17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.